REVIEW PAPER
Psoriasis and systemic lupus erythematosus in children – literature review based on case report
Zbigniew Żuber
5,6
1
4th Department of Pediatric Rheumatology and Endocrinology, Regional Specialized Children’s Hospital in Olsztyn, Poland
2
Department and Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland
3
Department of Rheumatology, Municipal Hospital Complex, Olsztyn, Poland
4
Department of Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
5
Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Poland
6
Ward for Older Children with Neurology and Rheumatology Subdivision, St. Louis Regional Specialized Children’s Hospital
in Krakow, Poland
Submission date: 2019-11-04
Final revision date: 2019-12-21
Acceptance date: 2020-01-29
Online publication date: 2020-02-28
Publication date: 2020-02-28
Reumatologia 2020;58(1):48-55
KEYWORDS
TOPICS
ABSTRACT
Immune-mediated inflammatory diseases are a group of diseases characterized by generalized inflammation that results from immune dysregulation, especially involving the mechanisms of acquired immunity. These diseases may be familial, showing that genetic factors play an important role in their development. Additionally, the occurrence of one disease makes a patient prone to other diseases. However, the coexistence of systemic lupus erythematosus (SLE) and psoriasis (Ps) is very rare due to their distinct genetic determinants and mechanisms of pathogenesis. Treatment is also challenging, as medications used to treat one condition exacerbate or even trigger the symptoms of the other. This paper presents the case of a Ps patient with a family history of autoimmune diseases, who developed systemic lupus erythematosus during puberty, as well as a discussion on the coexistence of SLE and Ps in developmental age based on available literature searching for PubMed database and American College of Rheumatology and European League Against Rheumatism abstracts particularly in this subject.
REFERENCES (37)
1.
Majdan M. Immune-Mediated Inflammatory Diseases and accompanying comorbidities. Wiad Lek 2016; 69: 611-615.
2.
Tselios K, Yap KS, Pakchotanon R, et al. Psoriasis in systemic lupus erythematosus: a single-center experience. Clin Rheumatol 2017; 36: 879-884, DOI: 10.1007/s10067-017-3566-0.
3.
Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017; 56: 1945-1961, DOI: 10.1093/rheumatology/kex260.
4.
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am 2012; 59: 345-364, DOI: 10.1016/j.pcl.2012.03.007.
5.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212, DOI: 10.1111/jdv.13854.
6.
Tan JAS, Tababa EJL, Dimacali CD, Yap-Silva C. Systemic Lupus Erythematosus with Coexistent Psoriasis Vulgaris: a case Report. Acta Medica Philippina 2017; 51: 347-350.
7.
Astudillo L, Sailler L, Carreiro M, et al. Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems. Ann Med Interne (Paris) 2003; 154: 3-6.
8.
Wang Y, Da G, Yu Y, et al. Coincident systemic lupus erythematosus and psoriasis vulgaris: a case report. G Ital Dermatol Venereol 2015; 150: 749-751.
9.
Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol 2018; 35: 170-181, DOI: 10.1111/pde.13382.
10.
Kuek A, Hazleman B, Ostör A. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007; 83: 251-260, DOI: 10.1136/pgmj.2006.052688.
11.
Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014; 27: 1-10.
12.
Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-350, DOI: 10.1056/NEJM200108023450506.
13.
Agalioti T, Villablanca EJ, Huber S, Gagliani N. Th17 cell plasticity: The role of dendritic cells and molecular mechanisms. J Autoimmun 2018; 87: 50-60, DOI: 10.1016/j.jaut.2017.12.003.
14.
Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010; 29: 10-15, DOI: 10.1016/j.sder. 2010.01.002.
15.
Andersen YMF, Wu JJ, Thyssen JP, Egeberg A. Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis. J Am Acad Dermatol 2019; 81: 1283-1291, DOI: 10.1016/j.jaad.2019.04.033.
16.
Rizzello F, Olivieri I, Armuzzi A. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Adv Ther 2018; 35: 545-562, DOI: 10.1007/s12325-018-0672-6.
17.
Blegvad C, Egeberg A, Tilde E, et al. Autoimmune Disease in Children and Adolescents with Psoriasis: A Cross-sectional Study in Denmark. Acta Dermato-Venereologica 2017; 97: 1225-1229, DOI: 10.2340/00015555-2743.
18.
Couture J, Bernatsky S, Scott S, et al. Risk of Childhood Rheumatic and NonRheumatic Autoimmune Diseases in Children Born to Women with Systemic Lupus Erythematosus. Arthritis Rheum 2018; 70: 1796-1800, DOI: 10.1002/art.40570.
19.
Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Supply (Stockh) 1996; 195: 1-15.
20.
Cuesta-Montero L, Belinchón I. Connective tissue diseases and psoriasis. Actas Dermosifiliogr 2011; 102: 487-497, DOI: 10.1016/j.ad.2011.03.002.
21.
Wallace DJ, Hahn BH (eds.). Dubois’ Lupus Erythematosus and Related Syndromes. W.B. Saunders, Philadelphia 2013.
22.
Shadakshari A, Yu J, Perl A. Association of psoriasis and psoriatic arthritis with systemic lupus erythematosus. 2013 ACR/ARHP Annual Meeting. October 25-30, 2013, San Diego, CA.
23.
O’Leary PA. Chronic lupus disseminatus and psoriasis vulgaris. Arch Dermatol Syphilol 1936; 15: 92.
24.
Wang Z, Zhu F, Wang J, et al. Increased CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells Correlate With Disease Severity in Systemic Lupus Erythematosus Patients in an iNOS-Dependent Manner. Front Immunol 2019; 10: 1202, DOI: 10.3389/fimmu.2019.01202.
25.
Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 2015; 18: 17-28, DOI: 10.1111/1756-185X.12528.
26.
Hahn BH. The pathogenesis of SLE. In: Wallace DJ, Hahn B (eds.). Dubois’ Lupus Erythematosus and Related Syndromes. Elsevier Saunders, Philadelphia 2010: 25-34.
27.
Pisetsky DS. The Complex Role of DNA, Histones and HMGB1 in the Pathogenesis of SLE. Autoimmunity 2014; 47: 487-493, DOI: 10.3109/08916934.2014.921811.
28.
Costner MI, Grau RH. Update on connective tissue diseases in dermatology. Semin Cutan Med Surg 2006; 25: 207-220, DOI: 10.1016/j.sder.2006.08.004.
29.
Owczarczyk-Saczonek A, Placek W. Łuszczyca jako choroba autoimmunologiczna [Psoriasis as an autoimmune disease]. Prz Dermatol 2014; 101: 278-287.
30.
Sin CZ, Wang TS, Chiu HY, Tsai TF. Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic. PloS One 2019; 14: e0210076, DOI: 10.1371/journal.pone.0210076.
31.
Minh VN, Thi VB, Van TC, et al. The Relationship between HLA-B27, HLA-Cw06, HLA-DR7 and Psoriatic Arthritis in Vietnamese Patients: Disease Progression and Therapeutic Burden. Open Access Maced J Med Sci 2019; 7: 300-301, DOI: 10.3889/oamjms.2019.064.
32.
Furue M, Kadono T. The contribution of IL-17 to the development of autoimmunity in psoriasis. Innate Immun 2019; 25: 337-343, DOI: 10.1177/1753425919852156.
33.
Wolska H, Błaszczyk M, Jabłońska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol 1989; 28: 98-103, DOI: 10.1111/j.1365-4362.1989.tb01327.x.
34.
Seminario-Vidal L, Hughey LS. Hydroxychloroquine de NovoInduced Psoriasis in a Patient with Lichen Planus Pigmentosus. Skinmed 2015; 13: 492–494.
35.
Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48: 716-720, DOI: 10.1093/rheumatology/kep080.
36.
Tierney E, Kirthi S, Ramsay B, Ahmad K. Ustekinumab-induced subacute cutaneous lupus. JAAD Case Rep 2019; 5: 271-273, DOI: 10.1016/j.jdcr.2019.01.015.
37.
Varada S, Gottlieb AB, Merola JF, et el. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol 2015; 72: 253-260, DOI: 10.1016/j.jaad.2014.10.038.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
